VRTX Vertex Pharmaceuticals Incorporated
$526.19
Vertex Pharmaceuticals Incorporated (VRTX) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is $4.28 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.7% since its last earnings release on August 3, 2026.
Vertex Pharmaceuticals Missed Expectations, Raises Guidance
Monday, August 3, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:00 PM ET
Earnings Whisper
-
vs $4.28
(GAAP)
Rev est $3.4B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$523.41
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.
Sector
Healthcare
Industry
Biotechnology
Held By 14 ETFs, by dollar flow
- QQQ Invesco QQQ Trust
- QQQ Invesco QQQ Trust
- QNXT iShares Nasdaq-100 ex Top 30 ETF
- QNXT iShares Nasdaq-100 ex Top 30 ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- XLV Health Care Select Sector SPDR Fund
- XLV Health Care Select Sector SPDR Fund
- IXJ iShares Global Healthcare ETF
- IXJ iShares Global Healthcare ETF
- BMED iShares Health Innovation Active ETF
- BMED iShares Health Innovation Active ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
Charts powered in part by Lightweight Charts™ by TradingView.